Abstract: In recent years, the number of poorly soluble drug entities coming out of drug discovery has increased significantly. These molecules demand utilization of different approaches to increase their solubility and/or dissolution rate and thus oral bioavailability. Fenoﬁbrate (FNB) is a lipophillic drug used in hypercholesterolemia and hypertriglyceridemia having log P 5.375, low solubility (practically insoluble in water) and low oral bioavailability (36%). Summary: This work provides a simple empirical tool using various drug-stabilizer interactions for rational selection of stabilizers. Efficient particle size reduction requires use of stabilizers that provide proper wetting of drug. Stabilizers that minimally affect intrinsic aqueous solubility of FNB resulted in lower mean particle size with better short term stability.References: A. Bhakay, M. Merwade, E. Bilgili, R.N. Dave, Novel aspects of wet milling for the production of microsuspensions and nanosuspensions of poorly water soluble drugs, Drug Dev. Ind. Pharm. 37 (2011) 963–976
Ask the author a question about this poster.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stanley Meyer Designs
Clinical Trial Summaries: Readability to Effectively Inform Patients
Autumn Sky Watson
The MODEL-AD consortium preclinical testing pipeline: pharmacokinetics and pharmacodynamics of prophylactic treatment with levetiracetam on the 5XFAD mouse model of Alzheimer’s Disease
SJ Sukoff Rizzo1, SK Quinney2, KD Onos1, KJ Keezer1, DR Jones2, AR Masters2, IF Metzger2, JA Meyer2, J Peters2, SC Persohn2, BR McCarthy2, AA Riley2, M Sasner1, G Howell1, H Williams1, AJ Oblak2, BL Lamb2, and PR Territo2
Validation of Factor IIa Assay for Dalteparin Sodium
Dr Amitabha De, Kiran Shah, Prajakta Ambre, Jyoti Gupta
Viajy Kumar Ranka